Patrick J. Heron - 23 Jun 2025 Form 4 Insider Report for HilleVax, Inc. (HLVX)

Reporting relationship: Director
Issuer ticker: HLVX
Reported as of: 23 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Jun 2025, 17:07:01 UTC
Prior SEC filing: 17 Jun 2025
Next SEC filing: 30 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Paul Bavier, Attorney-in-Fact for Patrick Heron

Key filing fact

Patrick J. Heron filed Form 4 for HilleVax, Inc. (HLVX) on 25 Jun 2025.

Key facts

This page summarizes Patrick J. Heron's Form 4 filing for HilleVax, Inc. (HLVX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 25 Jun 2025, 17:07.

Change

Previous filing in this sequence was filed on 17 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001365617 Primary reporting owner

Heron Patrick J

Relationship: Director
Address: C/O HILLEVAX, INC.,, 321 HARRISON AVE, SUITE 500, BOSTON
Signature: /s/ Paul Bavier, Attorney-in-Fact for Patrick Heron
Signature date: 25 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HLVX transaction

Common Stock

Award

Transaction value: $0
Shares: +17,199
Change %
Price: $0.000000
Shares after: 17,199
Date: 23 Jun 2025
Ownership: Direct
Footnotes: F1

HLVX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 8,535,337
Date: 23 Jun 2025
Ownership: By Frazier Life Sciences X, L.P.
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Restricted Stock Units ("RSUs") were granted on June 23, 2025 pursuant to the Registrant's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (i) the first anniversary of the date of grant or (ii) a Change in Control (as defined in the Registrant's 2022 Incentive Award Plan), in each case, subject to the non-employee director continuing in service on the Registrant's board of directors through such vesting date.

Footnote F2

The shares reported herein are held of record by Frazier Life Sciences X, L.P. ("FLS X"). The general partner of FLS X is FHMLS X, L.P., and the general partner of FHMLS X, L.P. is FHMLS X, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.